Calendario›REGN›Trevogrumab-Part A · COURAGE

Trevogrumab-Part A · COURAGE

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

Ensayo de REGENERON PHARMACEUTICALS, INC. en Obesidad.

Más ensayos de: Obesidad.

Fase

Fase 2

Estado

En marcha, sin reclutar

Participantes

1.005

previstos

Centros

60

Fin del objetivo primario

jun 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en mar 2024.

Qué mide

Incidence of treatment-emergent adverse events (TEAEs) (del registro, en inglés) (del inicio a la semana 7)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06299098), actualizada en ago 2026.